Weighted Average Number of Shares Outstanding, Diluted of Oruka Therapeutics, Inc. from 30 Jun 2010 to 30 Jun 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Oruka Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 30 Jun 2010 to 30 Jun 2025.
  • Oruka Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 30 Jun 2025 was 42,095,951, a 1216% increase year-over-year.
  • Oruka Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 16,789,362, a 16% increase from 2023.
  • Oruka Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 14,415,877, a 0.04% increase from 2022.
  • Oruka Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 14,410,143, a 3.6% increase from 2021.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Oruka Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 42,095,951 +38,897,976 +1216% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 41,679,560 +27,178,417 +187% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 16,789,362 +2,373,485 +16% 01 Oct 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
Q3 2024 15,013,655 +603,512 +4.2% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 3,197,975 -11,212,168 -78% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 14,501,143 +91,000 +0.63% 01 Jan 2024 31 Mar 2024 10-Q 25 Apr 2024 2024 Q1
Q4 2023 14,415,877 +5,734 +0.04% 01 Oct 2023 31 Dec 2023 10-K 01 Feb 2024 2023 FY
Q3 2023 14,410,143 0 0% 01 Jul 2023 30 Sep 2023 10-Q 18 Oct 2023 2023 Q3
Q2 2023 14,410,143 0 0% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 14,410,143 0 0% 01 Jan 2023 31 Mar 2023 10-Q 25 Apr 2024 2024 Q1
Q4 2022 14,410,143 01 Oct 2022 31 Dec 2022 10-K 01 Feb 2024 2023 FY
Q3 2022 14,410,143 0 0% 01 Jul 2022 30 Sep 2022 10-Q 18 Oct 2023 2023 Q3
Q2 2022 14,410,143 0 0% 01 Apr 2022 30 Jun 2022 10-Q 21 Jul 2023 2023 Q1
Q1 2022 14,410,143 01 Jan 2022 31 Mar 2022 10-Q 24 Apr 2023 2023 Q1
Q3 2021 14,410,143 01 Jul 2021 30 Sep 2021 10-Q 28 Oct 2022 2022 Q3
Q2 2021 14,410,143 01 Apr 2021 30 Jun 2021 10-Q 02 Aug 2022 2022 Q2
Q2 2012 12,166,301 +1,916,123 +19% 01 Apr 2012 30 Jun 2012 10-Q 13 Aug 2012 2012 Q2
Q2 2011 10,250,178 +1,517,341 +17% 01 Apr 2011 30 Jun 2011 10-Q 13 Aug 2012 2012 Q2
Q2 2010 8,732,837 01 Apr 2010 30 Jun 2010 10-Q 15 Aug 2011 2011 Q2

Oruka Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 16,789,362 +2,373,485 +16% 06 Feb 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
2023 14,415,877 +5,734 +0.04% 01 Jan 2023 31 Dec 2023 10-K 01 Feb 2024 2023 FY
2022 14,410,143 +506,272 +3.6% 01 Jan 2022 31 Dec 2022 10-K 01 Feb 2024 2023 FY
2021 13,903,871 01 Jan 2021 31 Dec 2021 10-K 24 Feb 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.